NDC product
Theraflu Nighttime Multi-Symptom Severe Cold Powder
NDC 0067-8124 · GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Key facts
| Product NDC | 0067-8124 |
|---|---|
| Proprietary name | Theraflu Nighttime Multi-Symptom Severe Cold Powder |
| Labeler | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Marketing start | Jul 15, 2015 |
| Marketing end | Dec 22, 2023 |
| Listing certified through | Dec 22, 2023 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: